Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share from the same period last year.
Huntington Ingalls Industries Reaffirms 2024 Guidance: Sees Shipbuilding Revenue Of $8.8B-$9.1B, Free Cash Flow Of $600-$700M,
HII Financial Outlook1
Reaffirming FY24 outlook
Reaffirming 5 year (2024-2028) free cash flow2,3 outlook of $3.6B
FY24 Outlook1
Shipbuilding
